CytoMed Therapeutics
GDTC
2 hedge funds and large institutions have $21.5K invested in CytoMed Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
23% less capital inflows, than outflows
Capital inflows: $14.7K | Capital outflows: $19K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$11.4K |
| 2 |
Tower Research Capital (TRC)
New York
|
+$3.32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Summit Securities Group
New York
|
-$19K |
GDTC Hedge Fund Activity: Q4 2023 in Review
2 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in CytoMed Therapeutics (GDTC) for Q4 2023, worth a combined $21.5K — up 3.9% from $20.7K a quarter earlier.
Fund positioning in GDTC was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was UBS Group, adding an estimated $11.4K. The largest seller was Summit Securities Group, exiting entirely with an estimated $19K sold.
- 2 institutional investors held CytoMed Therapeutics (GDTC) as of Q4 2023, unchanged from Q3 2023.
- Funds reported $21.5K of CytoMed Therapeutics stock for Q4 2023, up 3.9% quarter-over-quarter.
- 1 fund opened new CytoMed Therapeutics positions in Q4 2023 and 1 closed out, a net change of 0 holders.
- The largest CytoMed Therapeutics buyer in Q4 2023 was UBS Group, an estimated $11.4K added.
- The largest CytoMed Therapeutics seller in Q4 2023 was Summit Securities Group, an estimated $19K sold.
Based on aggregated 13F filings for Q4 2023.